المؤلفون: E. Kovalenko I., E. Artamonova V., L. Bolotina V., L. Zhiliaeva A., D. Ponomarenko M., E. Karabina V., G. Mukhametshina Z., A. Khasanova I., E. Ratner Yu., A. Safarova R., A. Manikhas G., N. Popova O., I. Evstigneeva V., L. Vladimirova Yu., L. Kramskaya V., T. Karandeeva V., I. Suslova R., O. Romanchuk V., V. Shikina E., A. Povyshev Yu., M. Osipov A., E. Cherniakova M., A. Dergunov S., M. Volkonskiy V., I. Chernov S., I. Shumskaya E., M. Fael M., V. Garifullina I., I. Gudkova E., Е. Коваленко И., Е. Артамонова В., Л. Болотина В., Л. Жиляева А., Д. Пономаренко М., Е. Карабина В., Г. Мухаметшина З., А. Хасанова И., Е. Ратнер Ю., А. Сафарова Р., А. Манихас Г., Н. Попова О., И. Евстигнеева В., Л. Владимирова Ю., Л. Крамская В., Т. Карандеева В., И. Суслова Р., О. Романчук В., В. Шикина Е., А. Повышев Ю., М. Осипов А., Е. Чернякова М., А. Дергунов С., М. Волконский В., И. Чернов С., И. Шумская Э., М. Фаель М., В. Гарифуллина И., И. Гудкова Е.

المساهمون: Данная публикация подготовлена при финансовой поддержке компании «Эйсай».

المصدر: Meditsinskiy sovet = Medical Council; № 20 (2021); 36-46 ; Медицинский Совет; № 20 (2021); 36-46 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: breast cancer, eribulin, trastuzumab, efficacy, tolerance, рак молочной железы, эрибулин, трастузумаб, эффективность, переносимость

وصف الملف: application/pdf

العلاقة: https://www.med-sovet.pro/jour/article/view/6578/5961Test; Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177–182. https://doi.org/10.1126/science.3798106Test.; Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–792. https://doi.org/10.1056/NEJM200103153441101Test.; Seidman A., Hudis C., Pierri M.K., Shak S., Paton V., Ashby M. et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20(5):1215–1221. https://doi.org/10.1200/JCO.2002.20.5.1215Test.; Cortazar P., Justice R., Johnson J., Sridhara R., Keegan P., Pazdur R. US Food and Drug Administration approval overview in metastatic breast cancer. J Clin Oncol. 2012;30(14):1705–1711. https://doi.org/10.1200/JCO.2011.39.2613Test.; Infante J.R., Yardley D.A., Burris H.A. 3rd, Greco F.A., Farley C.P., Webb C. et al. Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients with HER2-positive metastatic breast cancer. Clin Breast Cancer. 2009;9(1):23–28. https://doi.org/10.3816/CBC.2009.n.004Test.; Livingston R.B., Barlow W.E., Kash J.J., Albain K.S., Gralow J.R., Lew D.L. et al. SWOG S0215: a phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer. Breast Cancer Res Treat. 2011;130(1):123–131. https://doi.org/10.1007/s10549-011-1698-5Test.; Swain S.M., Baselga J., Kim S.B., Ro J., Semiglazov V., Campone M. et al. CLEOPATRA Study Group. Pertuzumab, trastuzumab, and docetaxel in HER2- positive metastatic breast cancer. N Engl J Med. 2015;372(8):724–734. https://doi.org/10.1056/NEJMoa1413513Test.; Geyer C.E., Forster J., Lindquist D., Chan S., Romieu C.G., Pienkowski T. et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355(26):2733–2743. https://doi.org/10.1056/NEJMoa064320Test.; Lewis Phillips G.D., Li G., Dugger D.L., Crocker L.M., Parsons K.L., Mai E. et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008;68(22):9280–9290. https://doi.org/10.1158/0008-5472.CAN-08-1776Test.; Barok M., Tanner M., Köninki K., Isola J. Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo. Breast Cancer Res. 2011;13(2):R46. https://doi.org/10.1186/bcr2868Test.; Verma S., Miles D., Gianni L., Krop I.E., Welslau M., Baselga J. et al.; EMILIA Study Group. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783–1791. https://doi.org/10.1056/NEJMoa1209124Test.; Krop I.E., Kim S.B., Martin A.G., LoRusso P.M., Ferrero J.M., BadovinacCrnjevic T. et al. Trastuzumab emtansine versus treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol. 2017;18(6):743–754. https://doi.org/10.1016/S1470-2045Test(17)30313-3.; Modi S., Saura C., Yamshita T., Park Y.H., Kim S., Tamura K. et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med. 2020;382:610–621. https://doi.org/10.1056/NEJMoa1914510Test.; Murthy R.K., Loi S., Okines A., Paplomata E., Hamilton E., Hurvitz S.A. et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. N Engl J Med. 2020;382:597–609. https://doi.org/10.1056/NEJMoa1914609Test.; Giordano S.H., Temin S., Chandarlapaty S., Crews J.R., Esteva F.J., Kirshner J.J. et al. Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2018;36(26):2736–2740. https://doi.org/10.1200/JCO.2018.79.2697Test.; Kaufman P.A., Awada A., Twelves C., Yelle L., Perez E.A., Velikova G. et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2015;33(6):594–601. https://doi.org/10.1200/JCO.2013.52.4892Test.; Twelves C., Cortes J., Vahdat L., Olivo M., He Y., Kaufman P.A., Awada A. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. Breast Cancer Res Treat. 2014;148(3):553–561. https://doi.org/10.1007/s10549-014-3144-yTest.; Pivot X., Marmé F., Koenigsberg R., Guo M., Berrak E., Wolfer A. Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy. Ann Oncol. 2016;27(8):1525–1531. https://doi.org/10.1093/annonc/mdw203Test.; Wilks S., Puhalla S., O’Shaughnessy J., Schwartzberg L., Berrak E., Song J. et al. Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2- positive breast cancer. Clin Breast Cancer. 2014;14(6):405–412. https://doi.org/10.1016/j.clbc.2014.04.004Test.; Inoue K., Ninomiya J., Saito T., Okubo K., Nakakuma T., Yamada H. et al.; SBCCSG-36 investigators. Eribulin, trastuzumab, and pertuzumab as firstline therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial. Invest New Drugs. 2019;37(3):538–547. https://doi.org/10.1007/s10637-019-00755-xTest.; Yamashita T., Masuda N., Saji S., Araki K., Ito Y., Takano T. et al. Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD). Trials. 2020;21(1):391. https://doi.org/10.1186/s13063-020-04341-yTest.; Lutrino E.S., Orlando L., Febbraro A., Giampaglia M., Zamagni C., Schiavone P. et al. Eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer patients: safety and efficacy. An Italian experience. Tumori. 2020;106(4):301–305. https://doi.org/10.1177/0300891619887225Test.; Коваленко Е.И., Артамонова Е.В., Карабина Е.В., Андреяшкина И.И., Прокофьева Е.А., Попова Н.О. и др. Эффективность комбинации эрибулина и трастузумаба при HER2-положительном диссеминированном раке молочной железы: результаты российского наблюдательного исследования. Современная онкология. 2020;22(1):29–35. https://doi.org/10.26442/18151434.2020.1.200058Test.; Krop I.E., Kim S.B., González-Martín A., LoRusso P.M., Ferrero J.M., Smitt M. et al.; TH3RESA study collaborators. Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(7):689–699. https://doi.org/10.1016/S1470-2045Test(14)70178-0.; Mougalian S.S., Copher R., McAllister L., Radtchenko J., Wang E.C., Broscious M. et al. Outcomes of real-world use of eribulin plus trastuzumab for HER2-positive metastatic breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4–8; San Antonio, TX. Philadelphia (PA)AACR. Cancer Res. 2019;79(4 Suppl.):17–28. https://doi.org/10.1158/1538-7445.SABCS18-P6-17-28Test.; https://www.med-sovet.pro/jour/article/view/6578Test

الإتاحة: https://doi.org/10.21518/2079-701X-2021-20-36-46Test
https://doi.org/10.1126/science.3798106Test
https://doi.org/10.1056/NEJM200103153441101Test
https://doi.org/10.1200/JCO.2002.20.5.1215Test
https://doi.org/10.1200/JCO.2011.39.2613Test
https://doi.org/10.3816/CBC.2009.n.004Test
https://doi.org/10.1007/s10549-011-1698-5Test
https://doi.org/10.1056/NEJMoa1413513Test
https://doi.org/10.1056/NEJMoa064320Test
https://doi.org/10.1158/0008-5472.CAN-08-1776Test

المؤلفون: M. Volkova I., A. Abdelgafur M., M. Aivazov T., Z. Amoev V., K. Babina G., P. Borisov S., A. Vorontsovа A., I. Evstigneeva V., O. Evsyukova I., O. Zhelezin V., A. Kalpinsky S., E. Karabina V., N. Kirdakova V., G. Kolesnikov P., E. Kuzmina S., D. Latipova Kh., R. Leonenkov V., M. Maturov R., A. Meskikh V., S. Mishugin V., E. Ovchinnikova G., A. Olshanskaya S., S. Protsenko A., T. Semiglazova Yu., R. Smirnov V., E. Usynin A., M. Fael M., E. Cherniakova M., I. Shumskaya E., М. Волкова И., А. Абдельгафур М., М. Айвазов Т., З. Амоев В., К. Бабина Г., П. Борисов С., А. Воронцова А., И. Евстигнеева В., О. Евсюкова И., О. Железин В., А. Калпинский С., Е. Карабина В., Н. Кирдакова В., Г. Колесников П., Е. Кузьмина С., Д. Латипова Х., Р. Леоненков В., М. Матуров Р., А. Меских В., С. Мишугин В., Е. Овчинникова Г., А. Ольшанская С., С. Проценко А., Т. Семиглазова Ю., Р. Смирнов В., Е. Усынин А., М. Фаэль М., Е. Чернякова М., И. Шумская Э.

المساهمون: The article was published with the financial support of Eisai Co., Ltd, Данная публикация подготовлена при финансовой поддержке компании «Эйсай»

المصدر: Cancer Urology; Том 15, № 3 (2019); 56-69 ; Онкоурология; Том 15, № 3 (2019); 56-69 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2019-15-3

مصطلحات موضوعية: lenvatinib in combination with everolimus, metastatic renal cell carcinoma, 2nd line therapy, комбинация ленватиниба с эверолимусом, диссеминированный почечно-клеточный рак, 2‑я линия терапии

وصف الملف: application/pdf

العلاقة: https://oncourology.abvpress.ru/oncur/article/view/984/870Test; Motzer R.J., Escudier B., Oudard S. et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372(9637):449–56. DOI:10.1016/S0140-6736(08)61039-9.; Motzer R.J., Escudier B., Oudard S. et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010;116(18): 4256–65. DOI:10.1002/cncr.25219.; Ko J.J., Xie W., Kroeger N. et al. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Lancet Oncol 2015;16(3):293–300. DOI:10.1016/S1470-2045(14)71222-7.; Носов Д.А., Волкова М. И., Гладков О. А. и др. Практические рекомендации по лекарственному лечению почечноклеточного рака. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2018. Том 8. С. 440–446.; NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer, version 3.2019.; Escudier B. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019. DOI:10.1093/annonc/mdz056.; Guidelines on Renal Cell Carcinoma. European Association of Urology (EAU), 2018. Pp. 34–40.; Eisenhauer E.A., Therasse P., Bogaerts J. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228–47. DOI:10.1016/j.ejca.2008.10.026.; http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htmTest.; IBM SPSS Statistics. Available at: http://www.predictive.ru/software/statistics.htmTest.; StatSoft. Available at: http://statsoft.ruTest.; Инструкция по медицинскому применению препарата ленватиниб. Регистрационный номер ЛП-003398 (с изменениями от 06.12.2016).; Инструкция по медицинскому применению препарата эверолимус. Регистрационный номер ЛП-002288.; Grünwald V., Bavbek S.E. An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. EJC 2012;48(3):324–32.; Motzer R. ESMO 2012 oral presentation; abstract LBA8_PR.; Rini B.I., Plimack E.R., Stus V. et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019;380(12):1116–27. DOI:10.1056/NEJMoa1816714.; Rini B.I. Poster presentation at the European Society for Medical Oncology (ESMO) Congress. October 19–23, 2018. Munich, Germany. Poster 875P.; Choueiri T.K., Hessel C., Halabi S. et al. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. Eur J Cancer. 2018;94:115–25. DOI:10.1016/j.ejca.2018.02.012.; Mollica V., Di Nunno V., Gatto L. et al. Resistance to systemic agents in renal cell carcinoma predict and overcome genomic strategies adopted by tumor. Cancers 2019;11(6):830. DOI:10.3390/cancers11060830.; De Lisi D., De Giorgi U., Lolli C. et al. Lenvatinib in the management of metastatic renal cell carcinoma: a promising combination therapy? Expert Opin Drug Metab Toxicol 2018;14(4):461–7. DOI:10.1080/17425255.2018.1455826.; Boss D.S., Glen H., Beijnen J.H. et al. A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours. Br J Cancer 2012;106(10):1598–604. DOI:10.1038/bjc.2012.154.; Molina A.M., Hutson T.E., Larkin J. et al. A phase 1b clinical trial of the multitargeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC). Cancer Chemother Pharmacol 2014;73(1):181–9. DOI:10.1007/s00280-013-2339-y.; Motzer R.J., Hutson T.E., Ren M. et al. Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma. Lancet Oncol 2016;17(1):e4–5. DOI:10.1016/S14702045(15)00543-4.; Motzer R.J., Hutson T.E., Glen H. et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol 2015;16(15):1473–82. DOI:10.1016/S1470-2045(15)00290-9.; Motzer R., Hutson T., Glen H. et al. Randomized phase II, three-arm trial of lenvatinib (LEN), everolimus (EVE), and LEN+EVE in patients (pts) with metastatic renal cell carcinoma (mRCC). Poster ASCO, Chicago, IL, 1 June 2015. Available at: https://meetinglibrary.asco.org/record/109690/abstractTest.; https://oncourology.abvpress.ru/oncur/article/view/984Test

الإتاحة: https://doi.org/10.17650/1726-9776-2019-15-3-56-69Test
https://doi.org/10.17650/1726-9776-2019-15-3Test
https://doi.org/10.1016/S0140-6736Test(08)61039-9
https://doi.org/10.1002/cncr.25219Test
https://doi.org/10.1016/S1470-2045Test(14)71222-7
https://doi.org/10.1093/annonc/mdz056Test
https://doi.org/10.1016/j.ejca.2008.10.026Test
https://doi.org/10.1056/NEJMoa1816714Test
https://doi.org/10.1016/j.ejca.2018.02.012Test
https://doi.org/10.3390/cancers11060830Test

المؤلفون: I. Evstigneeva

المصدر: Vrach. 33:83-89

مصطلحات موضوعية: Complementary and alternative medicine, Pharmaceutical Science, Pharmacology (medical)

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::0257642f3befaef85dc6ecee1b14c084Test
https://doi.org/10.29296/25877305-2022-09-17Test

المؤلفون: L. Manzyuk V., E. Kovalenko I., V. Gorbunova A., L. Bolotina V., T. Semiglazova Y., L. Zhilyaeva A., Y. Mishina A., D. Ponomarenko M., V. Goldberg E., N. Popova O., E. Karabina V., G. Mukhametshina Z., A. Khasanova I., S. Safina Z., M. Shaidorov V., L. Vladimirova Y., I. Mitashok S., E. Prokofieva P., I. Evstigneeva V., I. Andreyashkina I., N. Abramova A., I. Popova L., A. Teterich A., E Gaisina A., V. Chubenko A., S. Limareva V., N. Tikhanovskaya M., A. Storozhakova E., N. Samaneva Y., Y. Svetitskaya V., T. Snezhko A., E. Kalabanova A., A. Povyshev Y., I. Yudina V., L. Vorotilina V., T. Andreeva V., G. Tumanyan C., A. Kozyakov E., L. Gilmutdinova A., Л. Манзюк В., Е. Коваленко И., В. Горбунова А., Л. Болотина В., Т. Семиглазова Ю., Л. Жиляева А., Ю. Мишина А., Д. Пономаренко М., В. Гольдберг Е., Н. Попова О., Е. Карабина В., Г. Мухаметшина З., А. Хасанова И., С. Сафина З., М. Шайдоров В., Л. Владимирова Ю., И. Миташок С., Е. Прокофьева П., И. Евстигнеева В., И. Андреяшкина И., Н. Абрамова А., И. Попова Л., А. Тетерич А., Е. Гайсина А., В. Чубенко А., С. Лимарева В., Н. Тихановская М., А. Сторожакова Э., Н. Саманева Ю., Я. Светицкая В., Т. Снежко А., Е. Калабанова А., А. Повышев Ю., И. Юдина В., Л. Воротилина В., Т. Андреева В., Г. Туманян С., А. Козяков Е., Л. Гильмутдинова А.

المصدر: Malignant tumours; № 3 (2017); 46-56 ; Злокачественные опухоли; № 3 (2017); 46-56 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: metastatic breast cancer, chemotherapy, eribulin, метастатический рак молочной железы, химиотерапия, эрибулин

وصف الملف: application/pdf

العلاقة: https://www.malignanttumors.org/jour/article/view/391/337Test; Cardoso F., Harbeck N., Fallowfield L., Kyriakides S., Senkus E. Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann. Oncol., 2012, Vol. 23, pp. vii11–vii19.; Cortes J., O’Shaughnessy J., Loesch D. et al. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study, Lancet, 2011, Vol. 377, pp. 914–923.; Kaufman P. A., Awada A., Twelves C. et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane, J. Clin. Oncol., 2015, Vol. 33, pp. 594–601.; Twelves C., Awada A., Cortes J., Yelle I., Velikova G., Olivo M., Song J., Dutcus C., Kaufman P. Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer, Breast Cancer: Basic and Clinical Research, 2016, Vol. 10, pp 77–84.; Twelves C., Cortes J., Vandat L. et al. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. Breast Cancer Res. Treat., 2014, Vol. 148, pp. 553–561.; Pivot X., Marm F., Koenigsberg R., Guo M., Berrak E., Wolfer A. Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy, Annals of Oncology, 2016, Vol. 27, pp. 1525–1531.; Wilks Sh., Puhalla Sh., O’Shaughnessy J. et al. Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer, Clin. Breast Cancer, 2014, Vol. 14, No. 6, pp. 405–412.; Инструкция по медицинскому применению препарата Халавен® (РУ ЛП-001782 от 28.07.2012, с изменениями от 08.02.2017). [Instructions for the medical use of the drug Halaven® (RU LP-001782 dated 28.07.2012, as amended on 08.02.2017) (In Russ.)]; Blum J. L., Twelves C. J., Dutcus C. et al. Impact of the number of prior chemotherapy regimens on overall survival (OS) among subjects with locally recurrent or MBC treated with eribulin mesylate: results from the Phase III EMBRACE study. Presented at the 33rd Annual San Antonio Breast Cancer Symposium (SABCS), December 8–12, 2010, San Antonio, TX, USA, P6-13–01.; Towle M. J., Salvato K. A., Wels B. F. et al. Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions, Cancer Res., 2011, Vol. 71. No. 2. pp. 496–505.; Funahashi Y., Okamoto K., Adachi Y. et al. Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models, Cancer Sci., 2014, Vol. 105. No. 10. pp. 1334–1342.; Ueda S., Saeki T., Takeuchi H. et al. In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients a comparison to bevacizumab, Br. J. Cancer, 2016, Vol. 114, pp. 1212–1218.; Yoshida T., Ozawa Y., Kimura T. et al. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial – mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states, Br. J. Cancer, 2014, Vol. 110, pp. 1497–505.; https://www.malignanttumors.org/jour/article/view/391Test

الإتاحة: https://doi.org/10.18027/2224-5057-2017-3-46-56Test
https://www.malignanttumors.org/jour/article/view/391Test

المؤلفون: Ol'ga Ivanovna Evstigneeva, Iraida Anatol'evna Safiulova, O I Evstigneeva, I A Safiulova

المصدر: Терапевтический архив, Vol 83, Iss 1, Pp 29-32 (2011)

مصطلحات موضوعية: screening, dispersion mapping, experience, cardiovisor, Medicine

وصف الملف: electronic resource

العلاقة: https://ter-arkhiv.ru/0040-3660/article/view/30784Test; https://doaj.org/toc/0040-3660Test; https://doaj.org/toc/2309-5342Test

الوصول الحر: https://doaj.org/article/097c49250bea42a7b58af06bf17005d2Test

المؤلفون: S. A. Matveev, E. I. Evstigneeva, A. V. Lekanov, N. G. Yakovenko, A. D. Shirshov

المصدر: Russian Aeronautics. 62:502-507

مصطلحات موضوعية: Feature (computer vision), Computer science, Electronic engineering, Aerospace Engineering, Development (differential geometry), Net (mathematics), Laser beams, Wireless control, Communication channel

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::3293eb141d49266fe251dbaf6ee05938Test
https://doi.org/10.3103/s1068799819030206Test

المؤلفون: Alexey Manikhas, N. Popova, T. Karandeeva, A. Safarova, I. Evstigneeva, Larisa Bolotina, Guzel Mukhametshina, Irina V. Kolyadina, A. Khasanova, Dmitry Ponomarenko, Elena Kovalenko, R. Ekaterina, Elena Karabina, L. Kramskaya, Ludmila Manzyuk, I. Shumskaya, I. Suslova, M. Volkonsky, Larisa Zhilyaeva, Vera Gorbunova

المصدر: European Journal of Cancer. 138:S59

مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, business.industry, medicine.disease, Metastatic breast cancer, chemistry.chemical_compound, chemistry, Trastuzumab, Internal medicine, medicine, business, Eribulin, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::242c7a41dbceb73647084b375877da34Test
https://doi.org/10.1016/s0959-8049Test(20)30684-5

المؤلفون: O I, Evstigneeva, I A, Safiulova

المصدر: Terapevticheskii arkhiv. 83(1)

مصطلحات موضوعية: Adult, Aged, 80 and over, Electrocardiography, Cardiovascular Diseases, Body Surface Potential Mapping, Ambulatory Care, Models, Cardiovascular, Humans, Signal Processing, Computer-Assisted, Middle Aged, Aged

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=pmid________::6aa1a0eaf39f6718fef110587e388c09Test
https://pubmed.ncbi.nlm.nih.gov/21446199Test

المؤلفون: T. A. Palagina, N. A. Preobrazhenskii, E. I. Filippovich, G. S. Postnikova, A. N. Cherkasov, R. I. Evstigneeva

المصدر: Chemistry of Heterocyclic Compounds. 1:492-495

مصطلحات موضوعية: Pigment, biology, Chemistry, visual_art, Organic Chemistry, visual_art.visual_art_medium, Organic chemistry, biology.organism_classification, Bacteria

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::42e92eeb5f8650964d8abb429a0d1c46Test
https://doi.org/10.1007/bf00469925Test